Lowering ammonia to prevent complications in liver failure
Treatments studied
Part of Digestive system clinical trials.
This trial tests whether lowering ammonia levels with medications can prevent serious liver-related problems in people with acute-on-chronic liver failure who do not yet have confusion. Participation involves receiving medication to reduce ammonia, which may help avoid complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have acute-on-chronic liver failure (a sudden worsening of liver function in someone with chronic liver disease) of a certain severity (grade I or II).
- Your blood ammonia level must be high — at least 135 micrograms per deciliter (or 79.5 micromoles per liter).
- You must not have confusion, disorientation, or coma due to liver disease (overt hepatic encephalopathy).
- You must not have taken lactulose, rifaximin, or L-ornithine L-aspartate (LOLA) in the last 48 hours.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a treatment called plasma exchange (which removes harmful substances from your blood and replaces them with healthy plasma) can help improve the function of other organs, like the kidneys or lungs, in people with advanced liver failure. It aims to find out if this treatment helps you recover better and to identify markers that show if the treatment is working.
This study looks at people with liver cirrhosis who develop a sudden, severe worsening of their liver function (called acute-on-chronic liver failure). It aims to better understand this condition and how it affects patients in the intensive care unit, which could help improve care.
This trial tests an experimental drug for people with severe alcoholic hepatitis that did not improve with steroids. Participants should have a moderate level of organ failure, but not require a breathing tube or kidney dialysis.
This trial compares two treatments—BCAA supplements and rifaximin—to see which is better at preventing another episode of confusion or coma in people with cirrhosis who have already had one. If you qualify, you would receive one of these treatments for several months.
This trial tests whether taking the antibiotic rifaximin just before and after a living-donor liver transplant can help prevent early problems with the new liver. It may be an option for adults having this surgery at the study hospital.
This study tests whether adding a second medicine (diloxanide furoate) to the standard antibiotic (metronidazole) helps people recover from an amoebic liver abscess. If you have this condition and are otherwise healthy, this treatment might improve your recovery.
Hear when a new Acute-On-Chronic Liver Failure trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.